These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1649757)

  • 21. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.
    Hirsch EC
    Mol Neurobiol; 1994; 9(1-3):135-42. PubMed ID: 7888089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered brain metabolism of iron as a cause of neurodegenerative diseases?
    Gerlach M; Ben-Shachar D; Riederer P; Youdim MB
    J Neurochem; 1994 Sep; 63(3):793-807. PubMed ID: 7519659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does oxidative stress participate in nerve cell death in Parkinson's disease?
    Hirsch EC
    Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
    Zuo L; Motherwell MS
    Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurotoxicity and neuroprotection in Parkinson's disease.
    Lange KW; Youdim MB; Riederer P
    J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
    Edwin Shackelford R; Manuszak RP; Heard SC; Link CJ; Wang S
    Med Hypotheses; 2005; 64(4):736-41. PubMed ID: 15694690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain neurotransmitters and neuropeptides in Parkinson's disease.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
    Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemical neurotransmission in the parkinsonian brain.
    Rinne UK; Rinne JO; Rinne JK; Laakso K
    Med Biol; 1987; 65(2-3):75-81. PubMed ID: 2821331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of dopamine receptor in the striatum by iron: behavioral and biochemical correlates.
    Youdim MB; Ashkenazi R; Ben-Shachar D; Yehuda S
    Adv Neurol; 1984; 40():159-70. PubMed ID: 6695592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases.
    Dusek P; Roos PM; Litwin T; Schneider SA; Flaten TP; Aaseth J
    J Trace Elem Med Biol; 2015; 31():193-203. PubMed ID: 24954801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease.
    Labandeira-Garcia JL; Rodriguez-Pallares J; Dominguez-Meijide A; Valenzuela R; Villar-Cheda B; Rodríguez-Perez AI
    Mov Disord; 2013 Sep; 28(10):1337-42. PubMed ID: 23925977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thirty years of dopamine research.
    Carlsson A
    Adv Neurol; 1993; 60():1-10. PubMed ID: 8093570
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
    Brücke T; Riederer P
    Wien Med Wochenschr; 1986 Aug; 136(15-16):401-8. PubMed ID: 2878540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metal-induced hepatotoxicity.
    Britton RS
    Semin Liver Dis; 1996 Feb; 16(1):3-12. PubMed ID: 8723319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.